Aurora Cannabis Inc. announced that it has been granted Community Plant Variety Rights by the EU’s Community Plant Variety Office for its proprietary cultivars Farm Gas™ (SOT20R07-007) and Sourdough™ (ACB21T044). The rights give Aurora exclusive control over the commercial production and sale of these strains throughout the 27 EU member states for the duration of the protection period.
The grant of plant‑variety rights is a strategic win for Aurora, as it protects the company’s investment in breeding and research and prevents competitors from copying its genetics. With the rights in place, Aurora can now commercialize Farm Gas™ and Sourdough™ across the EU without the risk of infringement, ensuring a consistent supply of high‑potency, high‑quality products to patients in Germany, Poland, the UK, Canada and Australia. The exclusivity also positions Aurora to capture a larger share of the fast‑growing European medical cannabis market, where intellectual property is a key differentiator.
Aurora already sells these cultivars in Germany and Poland, and the new rights extend that presence to the rest of the EU. The company’s focus on genetics and R&D has led to a portfolio of differentiated strains such as Black Jelly and Daily Special™, and the EU protection reinforces Aurora’s reputation as a leader in cannabis breeding. By securing these rights, Aurora can maintain pricing power and protect margins in a market that increasingly rewards consistent, high‑quality products.
Lana Culley, Aurora’s Vice President of Innovation and International Operations, said the rights “recognize the exceptional genetics work underway at our Aurora Coast R&D facility and strengthen our global genetics portfolio.” She added that the protection “ensures our high‑quality, differentiated varieties can consistently reach patients and consumers worldwide, and that Aurora remains committed to advancing our unique breeding program.”
The move signals Aurora’s continued investment in high‑margin, differentiated products and underscores its long‑term growth strategy in the European medical cannabis market. By safeguarding its proprietary genetics, Aurora can better manage supply chain risks, maintain pricing power, and accelerate market penetration across the EU, positioning the company for sustained growth in a highly regulated industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.